Supplementary Information
nausea, leukopenia, inflammation, dizziness, CD4Effect
ADVERSE EVENTS, INFLAMMATION, SECONDARY, LEUKOPENIA
ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, The online version contains supplementary material available at 10.1186/s40035-023-00387-5.Regulatory T cells (Tregs) constitute a subset of T cells that play a protective role by suppressing inflammation [This study is an open-label, phase-1 trial, designed to evaluate the safety and feasibility of low-dose IL-2 to expand Tregs in AD individuals (All 8 patients completed the four-month treatment phase as well as the 2-month post-treatment follow-up phase. There were no serious adverse events reported following IL-2 administration. The most common adverse events were injection site irritation/redness (37.5%), mild leukopenia (37.5%), flu-like symptoms (12.5%), dizziness (12.5%) and nausea (12.5%). The percentage and immunophenotype of peripheral immune populations were assessed by flow cytometry. For the secondary endpoint, the CD4Effect of low-dose IL-2 treatment on immune parameters and cognitive status in AD subjects.The recently approved anti-amyloid immunotherapies offer partially effective treatment for a relatively small subset of the vast and expanding AD population [